Canadian regulator, Health Canada, has just issued a warning for lupus medication, Benlysta, over hypersensitivity and infusion reactions. Benlysta (belimumab) is a prescription drug approved for the treatment of adults diagnosed with lupus (systemic lupus erythematosus or SLE), who are also being treated with other medications for lupus. When initially approved, Benlysta’s Product Monograph contained […]
Canadian regulator, Health Canada, has just issued a warning for lupus medication, Benlysta, over hypersensitivity and infusion reactions.
Benlysta (belimumab) is a prescription drug approved for the treatment of adults diagnosed with lupus (systemic lupus erythematosus or SLE), who are also being treated with other medications for lupus.
When initially approved, Benlysta’s Product Monograph contained information and warnings about allergic (hypersensitivity) reactions occurring more often in patients treated with Benlysta, versus patients not treated with Benlysta, said Health Canada.
The Benlysta Product Monograph has been updated with the following information:
GlaxoSmithKline advised healthcare professionals, by letter, of the new safety information.
To report suspected adverse reactions to these or other health products, please contact Health Canada’s Canada Vigilance Program—to report adverse health product reactions—can be reached, toll-free, at 1.866.234.2345, or at the MedEffect™ Canada Web site at: http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php.